Boston Scientific Tops Q2 Forecasts and Lifts Full-Year EPS Outlook
BSX is trading near its 52-week low of $42.2 (10.0% above the low).
Summary
Boston Scientific posted Q2 2026 results above expectations, with 7.0% organic sales growth and adjusted EPS of $0.86, while raising its full-year adjusted EPS guidance and completing a $2 billion share buyback.
Key Events · Earnings and Guidance · BSX
-
Q2 Earnings Beat
Net sales of $5.442 billion grew 7.5% reported and 7.0% organic, surpassing the guidance range of 5.5–7.5% reported. Adjusted EPS of $0.86 exceeded the $0.82–$0.84 guidance.
-
Full-Year Guidance Raised
Full-year 2026 adjusted EPS guidance increased to $3.28–$3.32, up from the prior implied range. Organic sales growth is expected at 5–6%.
-
$2B Buyback Completed
The previously announced $2 billion accelerated share repurchase program was completed, retiring approximately 40 million shares, which will boost EPS.
-
Q3 Guidance In Line
Q3 2026 organic sales growth is guided to 3–5%, with adjusted EPS of $0.80–$0.82, reflecting typical seasonal patterns.
Analysis · BSX · Industrial Applications And Services
A strong second quarter saw organic sales climb 7.0% and adjusted EPS reach $0.86, clearing the top end of management's guidance. Confidence in sustained momentum prompted a raise in the full-year adjusted EPS outlook to $3.28–$3.32. Per-share metrics also get a lift from the completed $2 billion accelerated share repurchase, which retired roughly 40 million shares. The results land just two days after a major restructuring announcement, suggesting the company is pairing cost discipline with continued investment in high-growth areas like pulsed field ablation and TAVR.
At the time of this filing, BSX was trading at $46.41 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $68.5B. The 52-week trading range was $42.20 to $109.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.